Global and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Report & Forecast 2024-2034
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
Market Analysis and InsightsGlobal and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market
This report focuses on global and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) market, also covers the segmentation data of other regions in regional level and county level.
The global PEG-modified Drugs (Recombinant Proteins-Polypeptides) revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Scope and Market Size
PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces PEG-modified Drugs (Recombinant Proteins-Polypeptides) definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PEG-modified Drugs (Recombinant Proteins-Polypeptides) sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market
This report focuses on global and United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) market, also covers the segmentation data of other regions in regional level and county level.
The global PEG-modified Drugs (Recombinant Proteins-Polypeptides) revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period (2024-2034).
PEG-modified drugs have the following advantagesimproving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Scope and Market Size
PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For United States market, this report focuses on the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.
By Company
Merck Sharp & Dohme
Baxalta
Amgen
Roche
UCB S.A.
Enzon
Horizon Pharma
Biogen
SunBio
Qilu Pharmaceutical
Changchun Genescience Pharmaceutical
Xiamen Amoytop Biotech
Jiangsu Hengrui Pharmaceuticals
Hansoh Pharmaceuticak Group
CSPC Baike (Shandong) Biopharmaceutical
Xiamen Sano banger Biotechnology
Lunan Pharmaceutical Group
Xiamen Amoytop Biotech
JenKem Technology
Segment by Type
Jinyouli
Xin Rui Bai
Shenlida
Jin Saizeng
Pegbin
Fulaimei
Aido
Segment by Application
Nonmyeloid Malignancy
Slow Growth in Children
Viral Hepatitis
Adult Type 2 Diabetes
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces PEG-modified Drugs (Recombinant Proteins-Polypeptides) definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PEG-modified Drugs (Recombinant Proteins-Polypeptides) sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices